{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:49:25Z","timestamp":1791139765877,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01258-1","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:04:08Z","timestamp":1726473848000},"page":"2805-2825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-9987","authenticated-orcid":false,"given":"Adam P.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-802X","authenticated-orcid":false,"given":"Silky W.","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1756-0491","authenticated-orcid":false,"given":"Braulio","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gurrola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"Suppl 2","key":"1258_CR1","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-23. https:\/\/doi.org\/10.1136\/ard.2004.033217. (discussion ii24\u20135).","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1258_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341. https:\/\/doi.org\/10.1007\/s40265-014-0191-y.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"1258_CR3","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease PJ, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14\u20137. https:\/\/doi.org\/10.1136\/ard.2004.032482.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1258_CR4","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s12325-021-01698-7","volume":"38","author":"M Skornicki","year":"2021","unstructured":"Skornicki M, Prince P, Suruki R, et al. Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic health records database analysis. Adv Ther. 2021;38(5):2458\u201371. https:\/\/doi.org\/10.1007\/s12325-021-01698-7.","journal-title":"Adv Ther"},{"key":"1258_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13555-023-00929-9","volume":"13","author":"JF Merola","year":"2023","unstructured":"Merola JF, Ogdie A, Gottlieb AB, et al. Patient and physician perceptions of psoriatic disease in the United States: results from the UPLIFT survey. Dermatol Ther. 2023;13:1329\u201346. https:\/\/doi.org\/10.1007\/s13555-023-00929-9.","journal-title":"Dermatol Ther"},{"issue":"11","key":"1258_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2017.1375903","volume":"33","author":"A Gibofsky","year":"2017","unstructured":"Gibofsky A, Skup M, Mittal M, et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017;33(11):1945\u201353. https:\/\/doi.org\/10.1080\/03007995.2017.1375903.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1258_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.040.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1258_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170\u20133. https:\/\/doi.org\/10.7861\/clinmed.2021-0257.","journal-title":"Clin Med"},{"issue":"1","key":"1258_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1258_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, et al. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatol Treat. 2023;34(1):1\u201319. https:\/\/doi.org\/10.1080\/09546634.2023.2200870.","journal-title":"J Dermatol Treat"},{"key":"1258_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17:509\u201322. https:\/\/doi.org\/10.1007\/s40268-017-0215-7.","journal-title":"Drugs R D"},{"issue":"7","key":"1258_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.18553\/jmcp.2018.24.7.623","volume":"24","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Adejoro O, Chastek B, et al. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623\u201331. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.623.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1258_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09546634.2012.755255","volume":"24","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Johnson BH, Fox KM, et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatol Treat. 2013;24(5):369\u201373. https:\/\/doi.org\/10.3109\/09546634.2012.755255.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1258_CR14","first-page":"68","volume":"34","author":"I Olivieri","year":"2016","unstructured":"Olivieri I, Cortesi PA, De Portu S, et al. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clin Exp Rheumatol. 2016;34(1):68\u201375.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1258_CR15","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s12325-020-01262-9","volume":"37","author":"JJ Wu","year":"2020","unstructured":"Wu JJ, Pelletier C, Ung B, et al. Treatment switch patterns and healthcare costs in biologic-naive patients with psoriatic arthritis. Adv Ther. 2020;37(5):2098\u2013115. https:\/\/doi.org\/10.1007\/s12325-020-01262-9.","journal-title":"Adv Ther"},{"issue":"2","key":"1258_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40744-019-0158-2","volume":"6","author":"Y Song","year":"2019","unstructured":"Song Y, Betts KA, Lu Y, et al. Economic burden of switching to different biologic therapies among tumor necrosis factor inhibitor-experienced patients with psoriatic arthritis. Rheumatol Ther. 2019;6(2):285\u201397. https:\/\/doi.org\/10.1007\/s40744-019-0158-2.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"1258_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jdermsci.2021.01.002","volume":"101","author":"S Imafuku","year":"2021","unstructured":"Imafuku S, Kanai Y, Murotani K, et al. Utility of the dermatology life quality index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study. J Dermatol Sci. 2021;101(3):185\u201393. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.01.002.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"1258_CR18","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jaad.2019.01.039","volume":"80","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Regnier SA, Chirilov A, et al. Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019;80(6):1650\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.039.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1258_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/jdv.12576","volume":"29","author":"D H\u00e4gg","year":"2015","unstructured":"H\u00e4gg D, Sundstr\u00f6m A, Eriksson M, et al. Decision for biological treatment in real life is more strongly associated with the psoriasis area and severity index (PASI) than with the dermatology life quality index (DLQI). J Eur Acad Dermatol Venereol. 2015;29(3):452\u20136. https:\/\/doi.org\/10.1111\/jdv.12576.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1258_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.012.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1258_CR21","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/jdv.15443","volume":"33","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Palmer JB, Hur P, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2019;33(5):886\u201392. https:\/\/doi.org\/10.1111\/jdv.15443.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"20","key":"1258_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"1258_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"International Society for Pharmacoepidemiology","year":"2016","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1258_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"issue":"1","key":"1258_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"1258_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s1526-5900(03)00716-8","volume":"4","author":"MP Jensen","year":"2003","unstructured":"Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407\u201314. https:\/\/doi.org\/10.1016\/s1526-5900(03)00716-8.","journal-title":"J Pain"},{"issue":"3","key":"1258_CR27","first-page":"469","volume":"27","author":"G Ibrahim","year":"2009","unstructured":"Ibrahim G, Buch M, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27(3):469\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"1258_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7960151","volume":"2022","author":"Y-L Lin","year":"2022","unstructured":"Lin Y-L, Huang A, Yang C-Y, et al. Measurement of body surface area for psoriasis using U-net models. Comput Math Methods Med. 2022;2022:1\u20139. https:\/\/doi.org\/10.1155\/2022\/7960151.","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"1258_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23\u201331. https:\/\/doi.org\/10.3109\/09546634.2013.865009.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1258_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2340\/00015555-1237","volume":"92","author":"I Flytstr\u00f6m","year":"2012","unstructured":"Flytstr\u00f6m I, Stenberg B, Svensson A, et al. Patients\u2019 visual analogue scale: a useful method for assessing psoriasis severity. Acta Derm Venereol. 2012;92(4):347\u20138. https:\/\/doi.org\/10.2340\/00015555-1237.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1258_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr.22401","volume":"67","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res. 2015;67(2):264\u201372. https:\/\/doi.org\/10.1002\/acr.22401.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"1258_CR32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jval.2013.10.003","volume":"16","author":"P Swinburn","year":"2013","unstructured":"Swinburn P, Lloyd A, Boye K, et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013;16(8):1156\u201362. https:\/\/doi.org\/10.1016\/j.jval.2013.10.003.","journal-title":"Value Health"},{"issue":"4","key":"1258_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-027535","volume":"9","author":"B Strober","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):1\u20139. https:\/\/doi.org\/10.1136\/bmjopen-2018-027535.","journal-title":"BMJ Open"},{"issue":"2","key":"1258_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","volume":"9","author":"V Lewis","year":"2004","unstructured":"Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169\u201380. https:\/\/doi.org\/10.1111\/j.1087-0024.2004.09113.x.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1258_CR35","unstructured":"Yarnall M. Key differences between US rheumatologists' and dermatologists' management of psoriatic arthritis. Arthritis Rheumatol; 2022: American College of Rheumatology."},{"issue":"4","key":"1258_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.18553\/jmcp.2016.22.4.396","volume":"22","author":"SA Foster","year":"2016","unstructured":"Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. J Manag Care Spec Pharm. 2016;22(4):396\u2013405. https:\/\/doi.org\/10.18553\/jmcp.2016.22.4.396.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01258-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01258-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01258-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:03:15Z","timestamp":1729008195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01258-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01258-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"29 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip J. Mease: Has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, UCB Pharma, and Ventyx; speakers bureau fees from AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB Pharma; Andrew Blauvelt: Has served as a speaker (received honoraria) for Eli Lilly and Company and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant Sciences, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Merck, Microbion, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant Sciences, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka; Adam P. Sima, Marie Gurrola: Employees of CorEvitas, LLC; Silky W. Beaty: Employee at the time of the study and current shareholder of UCB Pharma; Robert Low, Braulio Gomez: Employees and shareholders of UCB Pharma; Mark G. Lebwohl: Employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly and Company, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB Pharma; consultant for Almirall, AltruBio Inc., AnaptysBio, Arcutis Inc., Arena Pharmaceuticals, Aristea Therapeutics, AstraZeneca, Avotres, BioMX, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, LLC, Dermavant Sciences, EPI, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Hexima Ltd, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, Strata, SUN Pharma, Trevi, Verrica, and Vial. Mark G. Lebwohl is an Editorial Board member of <i>Dermatology and Therapy<\/i>. Mark G. Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki [] and the Guidelines for Good Pharmacoepidemiology Practice []. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), (Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, before the site\u2019s participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}